Business Daily from THE HINDU group of publications
Friday, Apr 04, 2008
ePaper | Mobile/PDA Version
Business Daily from THE HINDU group of publications Friday, Apr 04, 2008 ePaper | Mobile/PDA Version |
|
|
|
|
|
|
|
Corporate
-
Announcements Marketing - New Products & Services
Our Bureau New Delhi, April 3 Ranbaxy Laboratories Ltd has announced the launch of BONISTA- Teriparatide injection for the treatment of Osteoporosis, in collaboration with the Hyderabad-based Virchow Biotech Pvt Ltd. Ranbaxy is the first company to launch this bio-generic product in the world. Commenting on the launch of the product, Mr Sanjeev I. Dani, Senior Vice-President and Regional Director (Asia & CIS), Ranbaxy, said, “With growing longevity, osteoporosis - a condition characterised by loss of bone mass, would gain increased attention. Ranbaxy has a number of new products in its pipeline including ‘Bonista’, for the osteoporosis patients who are normally treated by orthopaedics and gynaecologists. Bonista is also a classic example of our endeavours to offer quality biogeneric therapeutic options to doctors and an affordable and efficacious product to patients.” The osteoporosis segment has a market size of around Rs 219 crores. More Stories on : Announcements | New Products & Services | Ranbaxy Laboratories Ltd | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
 |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2008, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|